As­traZeneca's Ul­tomiris hits pri­ma­ry end­point for PhI­II NMOSD study

As­traZeneca caught a trio of re­cent wins — scor­ing an ex­pand­ed in­di­ca­tion for its breast can­cer drug En­her­tu, nail­ing Farx­i­ga’s Phase III win ear­li­er this week, and now, an­oth­er tri­al win.

The UK phar­ma said Thurs­day that its long-act­ing C5 com­ple­ment in­hibitor drug Ul­tomiris (ravulizum­ab-cwvz) hit on its pri­ma­ry end­point in the Phase III CHAM­PI­ON-NMOSD study. That end­point was to show a “sta­tis­ti­cal­ly sig­nif­i­cant and clin­i­cal­ly mean­ing­ful re­duc­tion in the risk of re­lapse in adults” with a spe­cif­ic type of a rare au­toim­mune dis­ease that tar­gets the cen­tral ner­vous sys­tem.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER